- New name expresses the Company’s vision to lead the next era of medicine - from
Japan , forJapan , and by extension, to the world – and its mission to accelerate the development of life-changing medicines, by investing in science and technology Sosei Group and its subsidiaries,Heptares Therapeutics and Idorsia Pharmaceuticals Japan andKorea , have all been renamed under the Nxera Pharma brand
The Group name and those of its subsidiaries have changed as follows:
Old name | New name |
“The Company decided that now is the optimal time to unify the business under a new name and bold brand. The name ’Nxera’ derives from the words ‘Next’ and ‘Era’ and our new motto – ‘Our Life’s Work is Life Itself’ – expresses our determination to lead the next era of medicine, leveraging our industry leading NxWave™ platform to drive advancements in our core disease areas of neurology, GI and immunology, metabolic disorders and rare diseases, in pursuit of new medicines for patients.”
“Our Company would not be where it is today without the dedication and effort of our truly international team, primarily in
–END–
About Nxera Pharma
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in
In addition to several products being commercialized in
Nxera employs over 350 talented people at key locations in
For more information, please visit www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma
Enquiries:
Nxera – Media and Investor Relations
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life
+44 (0)203 928 6900 | Nxera@medistrava.com
Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Nxera Pharma
2024 GlobeNewswire, Inc., source